CABOMETYX (Ipsen Pty Ltd)
Product name
CABOMETYX
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
198 working days (255)
Active ingredients
cabozantinib (S)-malate
Registration type
NCE/NBE
Indication
CABOMETYX is indicated for the treatment of advanced renal cell carcinoma (RCC) in adults following prior treatment with vascular endothelial growth factor targeted therapy.